D. E. Shaw & Co. Inc. Has $8.09 Million Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)

D. E. Shaw & Co. Inc. raised its stake in Bio-Rad Laboratories, Inc. (NYSE:BIO - Free Report) by 46.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 24,625 shares of the medical research company's stock after purchasing an additional 7,837 shares during the quarter. D. E. Shaw & Co. Inc. owned 0.09% of Bio-Rad Laboratories worth $8,090,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of BIO. Principal Financial Group Inc. lifted its holdings in shares of Bio-Rad Laboratories by 95.6% in the 3rd quarter. Principal Financial Group Inc. now owns 44,341 shares of the medical research company's stock valued at $14,836,000 after buying an additional 21,669 shares during the period. Park Avenue Securities LLC lifted its holdings in Bio-Rad Laboratories by 28.2% in the fourth quarter. Park Avenue Securities LLC now owns 2,291 shares of the medical research company's stock valued at $753,000 after acquiring an additional 504 shares during the period. Contravisory Investment Management Inc. purchased a new stake in shares of Bio-Rad Laboratories during the 4th quarter worth $569,000. Gateway Investment Advisers LLC grew its stake in shares of Bio-Rad Laboratories by 47.5% during the 4th quarter. Gateway Investment Advisers LLC now owns 1,158 shares of the medical research company's stock worth $380,000 after purchasing an additional 373 shares during the period. Finally, Wedge Capital Management L L P NC acquired a new stake in shares of Bio-Rad Laboratories in the fourth quarter valued at about $28,740,000. Institutional investors and hedge funds own 65.24% of the company's stock.

Bio-Rad Laboratories Stock Performance

BIO stock traded down $9.30 during trading on Wednesday, reaching $237.75. 16,465 shares of the company's stock were exchanged, compared to its average volume of 315,521. The company's fifty day moving average price is $243.42 and its 200-day moving average price is $296.91. The firm has a market cap of $6.47 billion, a PE ratio of -3.66 and a beta of 1.00. Bio-Rad Laboratories, Inc. has a 1-year low of $215.38 and a 1-year high of $387.99. The company has a quick ratio of 4.85, a current ratio of 6.48 and a debt-to-equity ratio of 0.18.

Bio-Rad Laboratories (NYSE:BIO - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical research company reported $2.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.73 by $0.81. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. The firm had revenue of $585.40 million for the quarter, compared to the consensus estimate of $573.01 million. During the same quarter in the previous year, the company earned $2.30 EPS. The business's revenue for the quarter was down 4.2% compared to the same quarter last year. On average, research analysts expect that Bio-Rad Laboratories, Inc. will post 10.81 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Royal Bank of Canada reduced their price target on shares of Bio-Rad Laboratories from $409.00 to $392.00 and set an "outperform" rating for the company in a research report on Friday, May 2nd. UBS Group cut their price target on Bio-Rad Laboratories from $355.00 to $310.00 and set a "buy" rating for the company in a research note on Friday, May 2nd. Citigroup lowered their price objective on shares of Bio-Rad Laboratories from $400.00 to $350.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. StockNews.com lowered Bio-Rad Laboratories from a "buy" rating to a "hold" rating in a research note on Monday, February 17th. Finally, Wells Fargo & Company dropped their price target on Bio-Rad Laboratories from $320.00 to $270.00 and set an "equal weight" rating for the company in a research report on Thursday, April 17th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, Bio-Rad Laboratories currently has an average rating of "Moderate Buy" and a consensus price target of $327.40.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.